3SBio files APX001 IND application with SFDA in China Apexigen.
APX001/SSS07 may be the second antibody discovered through the use of Apexigen’s technologies for which an IND has been filed with the SFDA. ‘We congratulate our colleagues at 3SBio upon this IND filing,’ said Dr. Xiaodong Yang, CEO and President of Apexigen. ‘It represents the effort of many individuals functioning collaboratively as a team to attain the common goal. We anticipate continuing success in our collaboration.’.. 3SBio files APX001 IND application with SFDA in China Apexigen, Inc., an emerging biopharmaceutical company centered on the discovery and development of monoclonal antibody therapeutics, today that its partner announced, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Medication software for APX001, also known as SSS07, with the State Meals and Drug Administration in China.This is simply not a surprise, nonetheless it is a clear signal that we need to keep this at heart when dealing with mental health issues, says Indredavik. Related StoriesCombatting viral and bacterial lung attacks with volatile anesthetics: an interview with Dr ChakravarthyResearchers identify potential brain-structured biomarker for depressive symptomsComputerised cognitive behavioural therapy likely to be ineffective in depression treatment Indredavik is one of the main contributors to the survey, along with PhD candidate Wenche Langfjord Mangerud at NTNU. They both just work at NTNU's Regional Centre for Child and Youth Mental Health insurance and Child Welfare. Mangerud emphasizes that physical pain and mental conditions can’t be treated individually.